ATHIRA PHARMA INC. - COMMON STOCK

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference

28 Mar 2023 01:00:00 By Nasdaq GlobeNewswire

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

23 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences

08 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences

06 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway

01 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

31 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Athira Pharma Provides 2023 Pipeline Outlook

05 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

21 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

05 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time

01 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference

29 Nov 2022 11:00:00 By Nasdaq GlobeNewswire

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

28 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

21 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference

16 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

10 Nov 2022 16:05:04 By Nasdaq GlobeNewswire

Athira Pharma to Present at Stifel 2022 Healthcare Conference

09 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference

07 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis

17 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

06 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

15 Aug 2022 16:05:02 By Nasdaq GlobeNewswire